化疗联合树突状细胞疫苗对乳腺癌微环境的修饰：一种选择最佳治疗策略的方法。
Modification of Breast Cancer Milieu with Chemotherapy plus Dendritic Cell Vaccine: An Approach to Select Best Therapeutic Strategies.
作者信息
Mejías Sosa Luis, López-Janeiro Álvaro, Córdoba Iturriagagoitia Alicia, Sala Pablo, Solans Belén P, Hato Laura, Inogés Susana, López-Díaz de Cerio Ascensión, Guillén-Grima Francisco, Espinós Jaime, De La Cruz Susana, Lozano María Dolores, Idoate Miguel A, Santisteban Marta
机构信息
Department of Pathology, Hospital Universitario Rey Juan Carlos, Gladiolo, 28933 Madrid, Spain.
Department of Pathology, Clínica Universidad de Navarra, Pío XII 14 Avenue 36, 31008 Pamplona, Spain.
出版信息
Biomedicines. 2023 Jan 17;11(2):238. doi: 10.3390/biomedicines11020238.
BACKGROUND
The addition of dendritic cell vaccines (DCV) to NAC could induce immune responses in those patients with residual disease (RD) by transforming the tumor microenvironment.
METHODS
Core diagnostic biopsies and surgical specimens from 80 patients (38 in the vaccinated group plus NAC (VG) and 42 in the control group (CG, treated only with NAC) were selected. We quantify TILs (CD8, CD4 and CD45RO) using immunohistochemistry and the automated cellular imaging system (ACIS III) in paired samples.
RESULTS
A CD8 rise in TNBC samples was observed after NAC plus DCV, changing from 4.48% in the biopsy to 6.70% in the surgical specimen, not reaching statistically significant differences ( = 0.11). This enrichment was seen in up to 67% of TNBC patients in the experimental arm as compared with the CG (20%). An association between CD8 TILs before NAC (4% cut-off point) and pathological complete response in the VG was found in the univariate and multivariate analysis (OR = 1.41, IC95% 1.05-1.90; = 0.02, and OR = 2.0, IC95% 1.05-3.9; = 0.03, respectively).
CONCLUSION
Our findings suggest that patients with TNBC could benefit from the stimulation of the antitumor immune system by using DCV together with NAC.
背景
在新辅助化疗（NAC）基础上加用树突状细胞疫苗（DCV）可通过改变肿瘤微环境诱导残留疾病（RD）患者产生免疫反应。
方法
选取80例患者的核心诊断活检组织和手术标本（接种疫苗组加NAC的患者38例（VG），对照组42例（CG，仅接受NAC治疗））。我们使用免疫组织化学和自动细胞成像系统（ACIS III）对配对样本中的肿瘤浸润淋巴细胞（TILs，CD8、CD4和CD45RO）进行定量分析。
结果
NAC加DCV治疗后，三阴乳腺癌（TNBC）样本中CD8水平升高，活检组织中从4.48%升至手术标本中的6.70%，但未达到统计学显著差异（P = 0.11）。与CG组（20%）相比，实验组高达67%的TNBC患者出现了这种富集现象。单因素和多因素分析发现，NAC治疗前CD8 TILs（截断点为4%）与VG组的病理完全缓解之间存在关联（OR = 1.41，95%置信区间1.05 - 1.90；P = 0.02，以及OR = 2.0，95%置信区间1.05 - 3.9；P = 0.03）。
结论
我们的研究结果表明，TNBC患者使用DCV联合NAC刺激抗肿瘤免疫系统可能会受益。
Zotero 插件